These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 30150078)

  • 41. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.
    Silvestro S; Mammana S; Cavalli E; Bramanti P; Mazzon E
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31013866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
    Samanta D
    Pediatr Neurol; 2019 Jul; 96():24-29. PubMed ID: 31053391
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cannabidiol for treatment of refractory childhood epilepsies: Experience from a single tertiary epilepsy center in Slovenia.
    Neubauer D; Perković Benedik M; Osredkar D
    Epilepsy Behav; 2018 Apr; 81():79-85. PubMed ID: 29526578
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigational cannabinoids in seizure disorders, what have we learned thus far?
    Ružić Zečević D; Folić M; Tantoush Z; Radovanović M; Babić G; Janković SM
    Expert Opin Investig Drugs; 2018 Jun; 27(6):535-541. PubMed ID: 29842819
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.
    Reithmeier D; Tang-Wai R; Seifert B; Lyon AW; Alcorn J; Acton B; Corley S; Prosser-Loose E; Mousseau DD; Lim HJ; Tellez-Zenteno J; Huh L; Leung E; Carmant L; Huntsman RJ
    BMC Pediatr; 2018 Jul; 18(1):221. PubMed ID: 29981580
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Second-line cannabis therapy in patients with epilepsy.
    Braun E; Gualano FM; Siddarth P; Segal E
    Clin Neurol Neurosurg; 2023 Apr; 227():107638. PubMed ID: 36870086
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Long-Term Effectiveness and Safety of Cannabidiol-Enriched Oil in Children With Drug-Resistant Epilepsy.
    Tzadok M; Hamed N; Heimer G; Zohar-Dayan E; Rabinowicz S; Ben Zeev B
    Pediatr Neurol; 2022 Nov; 136():15-19. PubMed ID: 36049378
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cannabinoids for drug-resistant seizures in a critically ill patient-Case report and literature review.
    Capra S; Narayan SW; Parratt K; Patanwala AE
    J Clin Pharm Ther; 2020 Jun; 45(3):570-572. PubMed ID: 31770462
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of cannabidiol in the treatment of epilepsy.
    Mazurkiewicz-Bełdzińska M; Zawadzka M
    Neurol Neurochir Pol; 2022; 56(1):14-20. PubMed ID: 35211946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Cagnetti C; Trinka E; Silvestrini M
    CNS Drugs; 2018 Oct; 32(10):905-916. PubMed ID: 30132269
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medical Marijuana in the Pediatric Population With Epilepsy-What You Should Know.
    Markle M; Nativio DG
    J Pediatr Health Care; 2019; 33(6):626-632. PubMed ID: 31160106
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.
    Dale T; Downs J; Olson H; Bergin AM; Smith S; Leonard H
    Epilepsy Res; 2019 Mar; 151():31-39. PubMed ID: 30771550
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cannabidiol-enriched oil in children and adults with treatment-resistant epilepsy-does tolerance exist?
    Uliel-Sibony S; Hausman-Kedem M; Fattal-Valevski A; Kramer U
    Brain Dev; 2021 Jan; 43(1):89-96. PubMed ID: 32713661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cannabidiol treatment of severe refractory epilepsy in children and young adults.
    Zilmer M; Olofsson K
    Dan Med J; 2021 Apr; 68(5):. PubMed ID: 33913416
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature.
    Moreira GA; Moraes Neto R; Ribeiro RG; Crippa ACS
    Rev Paul Pediatr; 2022; 41():e2021197. PubMed ID: 35830160
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy.
    Wheless JW; Dlugos D; Miller I; Oh DA; Parikh N; Phillips S; Renfroe JB; Roberts CM; Saeed I; Sparagana SP; Yu J; Cilio MR;
    CNS Drugs; 2019 Jun; 33(6):593-604. PubMed ID: 31049885
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
    Franco V; Perucca E
    Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cannabis for Pediatric Epilepsy.
    Huntsman RJ; Tang-Wai R; Shackelford AE
    J Clin Neurophysiol; 2020 Jan; 37(1):2-8. PubMed ID: 31895184
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
    Devinsky O; Cross JH; Laux L; Marsh E; Miller I; Nabbout R; Scheffer IE; Thiele EA; Wright S;
    N Engl J Med; 2017 May; 376(21):2011-2020. PubMed ID: 28538134
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study.
    Hausman-Kedem M; Menascu S; Kramer U
    Brain Dev; 2018 Aug; 40(7):544-551. PubMed ID: 29674131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.